{"title":"Frühes HR-positives Mammakarzinom","authors":"Katharina Arnheim","doi":"10.1055/a-2122-9825","DOIUrl":null,"url":null,"abstract":"Mit Ribociclib hat sich in der Phase-III-Studie NATALEE ein weiterer CDK4/6-Inhibitor in der adjuvanten Therapie des frühen HR-positiven (HR +), HER2-negativen (HER –) Brustkrebs bewährt.","PeriodicalId":122245,"journal":{"name":"Onkologische Welt","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkologische Welt","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2122-9825","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mit Ribociclib hat sich in der Phase-III-Studie NATALEE ein weiterer CDK4/6-Inhibitor in der adjuvanten Therapie des frühen HR-positiven (HR +), HER2-negativen (HER –) Brustkrebs bewährt.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
